Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice

被引:117
作者
Kawakami, S
Wong, J
Sato, A
Hattori, Y
Yamashita, F
Hashida, M [1 ]
机构
[1] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Drug Del Res, Sakyo Ku, Kyoto 6068501, Japan
[2] Baxter Healthcare Corp, IV Syst Div, Sci Affairs, Pharmaceut Sci R&D, Round Lake, IL 60073 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS | 2000年 / 1524卷 / 2-3期
关键词
drug delivery system; glycosylated liposome; targeting; asialoglycoprotein receptor; mannose receptor; fucose receptor;
D O I
10.1016/S0304-4165(00)00163-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The in vivo disposition behavior and pharmacokinetic characteristics of galactosylated (Gal), mannosylated (Man) and fucosylated (Fuc) liposomes were compared in this study. For the preparation of the glycosylated liposomes, cholesten-5-yloxy-N-(4-((1-imino-2-beta -D-thiogalactosylethyl)amino)alkyl)formamide (Gal-C4-Chol) (Kawakami et al., Biochem. Biophys. Res. Commun. 252 (1998) 78-83) and its mannosylated and fucosylated derivatives (Man-C4-Chol and Fuc-C4-Chol, respectively) were synthesized. The glycosylated liposomes are composed of distearoylphosphatidylcholine (DSPC), cholesterol (Chol), and Gal-C4-Chol (or Man-C4-Chol or Fuc-C4-Chol) with the molar ratio of 60:35:5. After intravenous injection in mice, these three types of [H-3]cholesteryl hexadecyl ether-labeled glycosylated liposomes were rapidly eliminated from the circulating blood and preferentially recovered in the liver. In contrast, DSPC/Chol (60:40) liposomes without glycosylation were retained for a long time in the circulating blood. The uptake ratios by parenchymal cells (PC) and nonparenchymal cells (NPC) (PC/NPC ratios) for 0.5% Gal, Man and Fuc liposomes were found to be 15.1, 0.6 and 0.2, respectively. The effect of predosing glycosylated proteins and liposomes on the hepatic uptake of 0.5% H-3-labeled Gal, Man, and Fuc liposomes was investigated and the results support the conclusion that Gal, Man, and Fuc liposomes are taken up by the liver via asialoglycoprotein receptors in PC, mannose receptors in NPC, and fucose receptors in NPC, respectively. Interestingly, Gal liposomes were taken up by NPC rather than by PC at a high dose (5%). Together with the finding that 5% Gal liposomes inhibit the hepatic uptake of H-3-labeled Fuc liposomes, this suggests that Gal-liposomes administered at a high dose will also be taken up by fucose receptors in NPC, that are considered to act as galactose particle receptors. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:258 / 265
页数:8
相关论文
共 37 条
[1]  
Akamatsu K, 1999, J PHARMACOL EXP THER, V290, P1242
[2]   Therapeutic opportunities for targeted liposomal drug delivery [J].
Allen, TM ;
Moase, EH .
ADVANCED DRUG DELIVERY REVIEWS, 1996, 21 (02) :117-133
[3]   SPECIFIC TARGETING OF THE ANTIVIRAL DRUG 5-IODO 2'DEOXYURIDINE TO THE PARENCHYMAL LIVER-CELL USING LACTOSYLATED POLY-L-LYSINE [J].
BIESSEN, EAL ;
BEUTING, DM ;
VIETSCH, H ;
BIJSTERBOSCH, MK ;
VANBERKEL, TJC .
JOURNAL OF HEPATOLOGY, 1994, 21 (05) :806-815
[4]   Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor [J].
Fiume, L ;
DiStefano, G ;
Busi, C ;
Mattioli, A ;
Bonino, F ;
TorraniCerenzia, M ;
Verme, G ;
Rapicetta, M ;
Bertini, M ;
Gervasi, GB .
JOURNAL OF VIRAL HEPATITIS, 1997, 4 (06) :363-370
[5]   Ligand-targeted liposomes [J].
Forssen, E ;
Willis, M .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 29 (03) :249-271
[6]   HEPATIC AND INTRAHEPATIC TARGETING OF AN ANTIINFLAMMATORY AGENT WITH HUMAN SERUM-ALBUMIN AND NEOGLYCOPROTEINS AS CARRIER MOLECULES [J].
FRANSSEN, EJF ;
JANSEN, RW ;
VAALBURG, M ;
MEIJER, DKF .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) :1215-1226
[7]   THERAPEUTIC EFFECTS OF SUPEROXIDE-DISMUTASE DERIVATIVES MODIFIED WITH MONOSACCHARIDES OR POLYSACCHARIDES ON HEPATIC-INJURY INDUCED BY ISCHEMIA REPERFUSION [J].
FUJITA, T ;
FURITSU, H ;
NISHIKAWA, M ;
TAKAKURA, Y ;
SEZAKI, H ;
HASHIDA, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 189 (01) :191-196
[8]   Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes [J].
Fukasawa, M ;
Shimizu, Y ;
Shikata, K ;
Nakata, M ;
Sakakibara, R ;
Yamamoto, N ;
Hatanaka, M ;
Mizuochi, T .
FEBS LETTERS, 1998, 441 (03) :353-356
[9]  
GARCON N, 1988, IMMUNOLOGY, V64, P743
[10]   PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING - PRINCIPLES AND APPLICATIONS [J].
GERLOWSKI, LE ;
JAIN, RK .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (10) :1103-1127